An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab

NCT05394792 · clinicaltrials.gov ↗
COMPLETED
Status
111
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AbbVie